JP2013529078A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529078A5
JP2013529078A5 JP2013510354A JP2013510354A JP2013529078A5 JP 2013529078 A5 JP2013529078 A5 JP 2013529078A5 JP 2013510354 A JP2013510354 A JP 2013510354A JP 2013510354 A JP2013510354 A JP 2013510354A JP 2013529078 A5 JP2013529078 A5 JP 2013529078A5
Authority
JP
Japan
Prior art keywords
seq
borrelia
composition
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529078A (ja
JP6227407B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036533 external-priority patent/WO2011143623A1/en
Publication of JP2013529078A publication Critical patent/JP2013529078A/ja
Publication of JP2013529078A5 publication Critical patent/JP2013529078A5/ja
Application granted granted Critical
Publication of JP6227407B2 publication Critical patent/JP6227407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013510354A 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法 Expired - Fee Related JP6227407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
US61/334,901 2010-05-14
PCT/US2011/036533 WO2011143623A1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016126608A Division JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法

Publications (3)

Publication Number Publication Date
JP2013529078A JP2013529078A (ja) 2013-07-18
JP2013529078A5 true JP2013529078A5 (enExample) 2014-06-26
JP6227407B2 JP6227407B2 (ja) 2017-11-08

Family

ID=44121257

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013510352A Expired - Fee Related JP6030052B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2013510354A Expired - Fee Related JP6227407B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013510352A Expired - Fee Related JP6030052B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Country Status (13)

Country Link
US (6) US8623375B2 (enExample)
EP (4) EP2569008B1 (enExample)
JP (6) JP6030052B2 (enExample)
KR (7) KR102130584B1 (enExample)
CN (3) CN103118701B (enExample)
AU (2) AU2011252844B2 (enExample)
BR (2) BR112012029058B1 (enExample)
CA (2) CA2799181C (enExample)
MX (3) MX340739B (enExample)
PL (2) PL2569008T3 (enExample)
RU (2) RU2636455C2 (enExample)
SI (2) SI2569009T1 (enExample)
WO (2) WO2011143623A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340739B (es) 2010-05-14 2016-07-22 Brookhaven Science Ass Llc Quimeras ospa y su uso en vacunas.
US8571937B2 (en) 2010-10-20 2013-10-29 Playspan Inc. Dynamic payment optimization apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
US10096022B2 (en) * 2011-12-13 2018-10-09 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
CN105229023B (zh) * 2013-03-15 2019-08-16 加利福尼亚大学董事会 源自线粒体的肽mots3调节代谢和细胞存活
US20160213766A1 (en) * 2013-09-23 2016-07-28 Ventria Bioscience, Inc. OspA Fusion Protein for Vaccination against Lyme Disease
HRP20250954T1 (hr) * 2014-01-09 2025-10-10 Valneva Austria Gmbh Mutantni fragmenti ospa i postupci i upotrebe koji se na njih odnose
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2016025331A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
KR20200047751A (ko) * 2015-08-14 2020-05-07 텔레호낙티에볼라게트 엘엠 에릭슨(피유비엘) 패킷 데이터 네트워크 연결을 관리하기 위한 노드 및 방법
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
EP3609911B1 (en) * 2017-04-13 2023-07-05 Valneva Austria GmbH Multivalent ospa polypeptides and methods and uses relating thereto
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
KR20210018205A (ko) 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
US20230398210A1 (en) 2020-04-09 2023-12-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
EP4132950A1 (en) * 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
KR20230121863A (ko) 2020-12-17 2023-08-21 아이덱스 래보러토리즈, 인코포레이티드 로키산 홍반열 검출 및 치료
EP4351777A4 (en) * 2021-06-07 2025-04-16 The University of Massachusetts Apparatus and method for the continuous production of RNA
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0536335A4 (en) * 1990-06-15 1993-07-14 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE168132T1 (de) 1991-02-15 1998-07-15 Uab Research Foundation Strukturgen von pneumokokken-protein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
WO1995012676A1 (en) * 1993-11-01 1995-05-11 Associated Universities, Inc. Chimeric proteins comprising borrelia polypeptides: uses therefor
CA2244110A1 (en) 1996-02-12 1997-08-14 Cobra Therapeutics Limited Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
ES2270523T3 (es) 1997-06-30 2007-04-01 The Administrators Of The Tulane Educational Fund Antigenos de superficie y proteinas utiles en composiciones para la diagnosis y prevencion de la enfermedad de lyme.
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
DE60131858T2 (de) * 2000-08-18 2008-12-04 The Research Foundation Of State University Of New York Borrelia burgdorferi rekombinante genkonstrukte
AU2001285049A1 (en) * 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
WO2004089969A2 (en) 2003-04-02 2004-10-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
BRPI0409459A (pt) * 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
BRPI0509079B8 (pt) * 2004-03-24 2021-07-06 Merck & Co Inc molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
WO2006014292A2 (en) 2004-07-02 2006-02-09 Dattwyler Raymond J Oral vaccine for borrelia
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
US7794727B2 (en) 2005-11-29 2010-09-14 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
US8293876B2 (en) 2007-02-22 2012-10-23 Baxter International Inc. Method of purification of hydrophobic proteins
BRPI0813644B8 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101909635B (zh) * 2008-01-11 2014-09-17 Vgx药品有限责任公司 针对多种登革病毒亚型的新颖疫苗
WO2009131665A1 (en) 2008-04-22 2009-10-29 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
MX340739B (es) 2010-05-14 2016-07-22 Brookhaven Science Ass Llc Quimeras ospa y su uso en vacunas.
WO2014018274A1 (en) * 2012-07-27 2014-01-30 Baxter International, Inc. Compositions comprising chimeric ospa molecules and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2013529077A5 (enExample)
RU2012153752A (ru) Химерные гены ospa, белки и способы их применения
RU2017144098A (ru) Гетеродимеризованный полипептид
JP6505110B2 (ja) ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用
CN101891806B (zh) 抗黄病毒包膜e蛋白的单克隆抗体及其应用
JP2015522270A5 (enExample)
US11352416B2 (en) Mosaic chimeric viral vaccine particle
CN109734800B (zh) 一种裂谷热病毒人源单克隆抗体及其应用
US12377138B2 (en) Treatment and prevention of malaria
CA3232870A1 (en) Coronavirus vaccines and methods of use
JP2015529677A5 (enExample)
CN102690789B (zh) 分泌破伤风外毒素单克隆抗体的杂交瘤细胞株及由其制备的单克隆抗体、Fab抗体与应用
Wei et al. Identification and characterization of protective epitope of Trichinella spiralis paramyosin
JP2023540779A (ja) コロナウイルス由来の受容体結合ドメイン及びヌクレオカプシドタンパク質を含む融合タンパク質及びその用途
CN112390884B (zh) Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
EP4347622A1 (en) Reconstitution and uses of flavivirus epitopes
EP3313435A1 (en) Novel vaccines in prevention and treatment of malaria
CN102219858A (zh) 微小隐孢子虫ctl多表位基因和融合蛋白及其应用
CN105254719B (zh) 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗
WO2023279803A1 (zh) Rbv的蛋白结合分子及其用途
CN107034198A (zh) 一种嵌合诺如病毒p颗粒及其制备和应用
CN110483624B (zh) 伽氏疏螺旋体OspA蛋白C端肽段及其应用
TW202306966A (zh) 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物
JP2023520990A5 (enExample)
CN104744593A (zh) 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用